What does this research mean for the field?

The newly developed spirocyclic BODIPY-based photosensitizer, BDP-I, achieves tumor-selective activation for photodynamic therapy by exploiting the acidic tumor microenvironment. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to enhance tumor selectivity in photodynamic therapy using a novel spirocyclic BODIPY photosensitizer.

May 20, 2026

A Spirocyclic BODIPY Photosensitizer with pH-Triggered Triplet-State Activation for Tumor-Selective Photodynamic Therapy

Key Points

This research aims to enhance tumor selectivity in photodynamic therapy using a novel spirocyclic BODIPY photosensitizer.
Developed BDP-I, a spirocyclic BODIPY photosensitizer targeting acidic microenvironments (pH 6.5-6.8).
Evaluated effectiveness in achieving selective activation under tumor conditions.
Assessed photodynamic therapy outcomes comparative to conventional methods.
BDP-I selectively activated in acidic tumor environments, enhancing efficacy.
Significantly improved tumor selectivity demonstrated compared to traditional photosensitizers.
Promoted tumor cell death with minimal effects on surrounding healthy tissue.

Abstract

Conventional photosensitizers for photodynamic therapy (PDT) suffer from poor tumor selectivity. Here, we develop BDP-I, a spirocyclic BODIPY-based photosensitizer that exploits the acidic tumor microenvironment (pH~6.5-6.8) to achieve selective activation....

Bookmark

A Spirocyclic BODIPY Photosensitizer with pH-Triggered Triplet-State Activation for Tumor-Selective Photodynamic Therapy

Key Points

Abstract

Cite This Study